Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results
Niels Teich, Internistische Gemeinschaftspraxis für Verdauungs-und Stoffwechselkrankheiten Leipzig und Schkeuditz, Leipzig 04105, Germany
Harald Grümmer, Praxis für Innere Medizin/Gastroenterologie, Potsdam 14471, Germany
Eric Jörgensen, Magen-Darm-Zentrum Remscheid, Remscheid 42859, Germany
Thomas Liceni, MVZ für Gastroenterologie am Bayerischen Platz, Berlin 10825, Germany
Frank Holtkamp-Endemann, Gastroenterologische Gemeinschaftspraxis am Germania-Campus, Münster 48159, Germany
Tim Fischer, Susanne Hohenberger, Medical Affairs, MSD Sharp and Dohme GmbH, Haar 85540, Germany
Author contributions: Hohenberger S contributed to study conception and study design; Teich N, Grümmer H, Jörgensen H, Liceni T and Holtkamp-Endemann F participated in the acquisition, analysis, and interpretation of the data, and drafted the initial manuscript; Hohenberger S and Fischer T reviewed the manuscript; all authors read and approved the final version of the manuscript.
Supported by MSD Sharp and Dohme GmbH, Haar, Germany.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board Ethics Committee of the Bavarian State Medical Association (Bayrische Landesärztekammer), Munich, Germany.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: Niels Teich has served as a speaker, a consultant and/or an advisory board member for AbbVie, Biogen, Falk Foundation, Janssen, MSD, Norgine, Takeda, Tillotts, Vifor and has received research funding from Ferring Arzneimittel GmbH; Harald Grümmer has received personal fees from MSD and AbbVie; Eric Jörgensen has received personal fees from MSD, Thomas Liceni has received personal fees from MSD, Frank Holtkamp-Endemann has received personal fees from MSD, Tim Fischer and Susanne Hohenberger are employees of MSD.
STROBE statement: The authors have read the STROBE statement-checklist of items, and the manuscript was prepared and revised according to the STROBE statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Niels Teich, MD, Internistische Gemeinschaftspraxis für Verdauungs-und Stoffwechselkrankheiten Leipzig und Schkeuditz, Nordstr. 21, Leipzig 04105, Germany. email@example.com
Received: February 6, 2020
Peer-review started: February 6, 2020
First decision: March 21, 2020
Revised: May 8, 2020
Accepted: May 23, 2020
Article in press: May 23, 2020
Published online: June 7, 2020